UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 23, 2026

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware1-361913-5315170

(State or other(Commission File(I.R.S. Employer

jurisdiction ofNumber)Identification No.)

incorporation)

66 Hudson Boulevard East10001-2192

New York, New York (Zip Code)

(Address of principal executive offices)

Registrant s telephone number, including area code:

(212) 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $0.05 par valuePFENew York Stock Exchange

1.000% Notes due 2027PFE/27

New York Stock Exchange

2.875% Notes due 2029

PFE/29

New York Stock Exchange

3.250% Notes due 2032

PFE/32

New York Stock Exchange

3.875% Notes due 2037

PFE/37A

New York Stock Exchange

4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders

(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 23, 2026.

(b) Shareholders voted on the matters set forth below.

1. The nominees for election to the Company s Board of Directors set forth in Item 1 to the Company s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 12, 2026 were elected to hold office until the Company s next Annual Meeting of Shareholders, based upon the following votes:

Nominee

Votes For

Votes Against

Abstentions

Broker non-vote

Ronald E. Blaylock3,442,653,662102,600,74811,374,500941,392,137

Albert Bourla3,261,211,737272,132,57323,284,563941,392,137

Mortimer J. Buckley3,403,974,675141,036,93211,617,303941,392,137

Susan Desmond-Hellmann3,401,932,807141,056,14713,639,956941,392,137

Joseph J. Echevarria2,929,511,380612,413,50214,702,274941,392,137

Scott Gottlieb3,415,886,776130,394,18510,343,738941,392,137

Dan R. Littman3,383,769,589161,740,87211,118,449941,392,137

Shantanu Narayen3,313,318,763231,613,93211,695,915941,392,137

Suzanne Nora Johnson3,272,936,863273,506,15110,185,896941,392,137

James Quincey3,453,778,74191,549,23611,300,933941,392,137

James C. Smith3,284,035,682261,217,69911,375,529941,392,137

Cyrus Taraporevala3,468,177,42376,665,72111,785,766941,392,137

2. The proposal to ratify the selection of KPMG LLP as the Company s independent registered public accounting firm for the 2026 fiscal year was approved based upon the following votes:

Votes for approval

4,160,827,231

Votes against

321,979,096

Abstentions

15,214,720

Broker non-votes

n/a

3. The proposal to approve the Pfizer Inc. 2019 Stock Plan, as amended April 2026 was approved based upon the following votes:

Votes for approval

3,227,692,578

Votes against

305,428,376

Abstentions

23,507,956

Broker non-votes

941,392,137

4. The proposal to approve, on an advisory basis, the 2026 compensation of the Company's Named Executive Officers was approved based upon the following votes:

Votes for approval

3,099,249,442

Votes against

423,935,881

Abstentions

33,443,287

Broker non-votes

941,392,137

5. The shareholder proposal to Adopt Adopt An Independent Chair Policy was not approved based upon the following votes:

Votes for approval

1,015,206,372

Votes against

2,509,042,021

Abstentions

32,354,566

Broker non-votes

941,392,137

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PFIZER INC.

Dated: April 27, 2026By:/s/ Margaret M. Madden

Margaret M. Madden

Senior Vice President and Corporate Secretary

Chief Governance Counsel